Medasense Biometrics Ltd.

Medasense Biometrics Ltd. specializes in advanced pain management solutions, focusing on real-time pain assessment through its innovative technology, enhancing patient care across healthcare environments. Founded in 2008 in Ramat Gan, Israel, Medasense Biometrics Ltd. develops sophisticated pain monitoring solutions.

The company has completed 4 funding deals, with its latest being a Series C round in September 2020, raising USD 18. 00 mn from investors including Asabys Partners and Baxter Ventures. Galit Zuckerman is both the CEO and founder. Medasense offers its flagship PMD-200™ product, which employs NOL® (Nociception Level) AI technology to assess pain responses in real time, allowing healthcare professionals to optimize pain management.

This device is utilized in critical care settings and has been implemented in markets like the United States, Europe, Canada, South Africa, the UAE, Israel, and select countries in Latin America. The company is also developing additional products to enhance pain prediction and prevention capabilities. Medasense's revenue model is based on sales of the PMD-200™ device and associated services, primarily targeting hospitals and healthcare facilities. Revenue is generated through device sales, which often include ongoing support and training.

The PMD-200™ is positioned as a critical asset in operating rooms and intensive care settings, where effective pain management is crucial for patient outcomes. Following its Series C funding round in September 2020, in which Medasense Biometrics Ltd. raised USD 18. 00 mn, the company plans to leverage these funds for expanding its product lineup and entering new geographic markets.

Specifically, Medasense aims to launch new pain management solutions and enhance existing offerings by targeting healthcare systems in additional regions, although specific timelines and market details have not been disclosed.